Flaxseed combined with low-dose estrogen therapy preserves bone tissue in ovariectomized rats

Menopause

Volumn 16, Issue 3, 2009, Pages 545-554

  Sacco, Sandra M ^a   Jiang, Jessica M Y ^a   Reza López, Sandra ^a   Ma, David W L ^a,b   Thompson, Lilian U ^a   Ward, Wendy E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

Author keywords

Bone; Flaxseed; Lignans; Low dose estrogen therapy; N 3 polyunsaturated fatty acids; Ovariectomized rats.

Indexed keywords

ARACHIDONIC ACID; ESTROGEN; ICOSAPENTAENOIC ACID; LIGNAN; LINOLEIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE TISSUE; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; FEMUR; FOOD INTAKE; LINSEED; LIPID COMPOSITION; LOW DRUG DOSE; LUMBAR VERTEBRA; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; RAT; TIBIA; UTERUS WEIGHT;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; FLAX; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; TIBIA;

EID: 67649884790     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31818fc00a     Document Type: Article

References (55)

1. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
2. North American Menopause Society. Estrogen and progesterone use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602.
3. International Menopause Society. HRT in the early menopause: scientific evidence and common perceptions. March 29-30, 2008. Available at: http://www.imsociety.org/comments-and-press-statements.html. Accessed July 22, 2008.
4. Richman S, Edusa V, Fadiel A, Naftolin F. Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy. Menopause 2006;13:148-155.
5. Mahady GB, Parrot J, Lee C, Yun GS, Dan A. Botanical dietary supplement use in peri- and postmenopausal women. Menopause 2003;10: 65-72.
6. Weiler HA, Kovacs H, Nitschmann E, Bankovic-Calic N, Aukema H, Ogborn M. Feeding flaxseed oil but not secoisolariciresinol diglucoside results in higher bone mass in healthy rats and rats with kidney disease. Prostaglandins Leukot Essent Fatty Acids 2007;76:269-275.
7. Kim MK, Chung BC, Yu VY, et al. Relationships of urinary phyto-oestrogen excretion to BMD in postmenopausal women. Clin Endocrinol (Oxf) 2002;56:321-328.
8. Mollard RC, Gillam ME, Wood TM, Taylor CG, Weiler HA. (n-3) Fatty acids reduce the release of prostaglandin E2 from bone but do not affect bone mass in obese (fa/fa) and lean Zucker rats. J Nutr 2005; 135:499-504.
9. Sakaguchi K, Morita I, Murota S. Eicosapentaenoic acid inhibits bone loss due to ovariectomy in rats. Prostaglandins Leukot Essent Fatty Acids 1994;50:81-84.
10. Watkins BA, Li Y, Seifert MF. Dietary ratio of n-6/n-3 PUFAs and docosahexaenoic acid: actions on bone mineral and serum biomarkers in ovariectomized rats. J Nutr Biochem 2006;17:282-289.
11. Griel AE, Kris-Etherton PM, Hilpert KF, Zhao G, West SG, Corwin RL. An increase in dietary n-3 fatty acids decreases a marker of bone re-sorption in humans. Nutr J 2007;6:2-9.
12. Thompson LU, Robb P, Serraino M, Cheung F. Mammalian lignan production from various foods. Nutr Cancer 1991;16:43-52.
13. Kardinaal AFM, Morton MS, Brüggemann-Rotgans IE, van Beresteijn EC. Phyto-oestrogen excretion and rate of bone loss in postmenopausal women. Eur J Clin Nutr 1998;52:850-855.
14. Dodin S, Lemay A, Jacques H, Légaré F, Forest JC, Masse B. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab 2005;90:1390-1397.
15. Brooks JD, Ward WE, Lewis JE, et al. Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy. Am J Clin Nutr 2004;79:318-325.
16. Lucas EA, Wild RD, Hammond LJ, et al. Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab 2002;87:1527-1532.
17. Cohen SL, Moore AM, Ward WE. Flaxseed oil and inflammation-associated bone abnormalities in interleukin-10 knockout mice. J Nutr Biochem 2005;16:368-374.
18. Power KA, Ward WE, Chen JM, Saarinen NM, Thompson LU. Flaxseed and soy protein isolate, alone and in combination, differ in their effect on bone mass, biomechanical strength, and uterus in ovari-ectomized nude mice with MCF-7 human breast tumor xenografts. J Toxicol Environ Health A 2007;70:1888-1896.
19. Power KA, Ward WE, Chen JM, Saarinen NM, Thompson LU. Genistein alone and in combination with the mammalian lignans enterolactone and enterodiol induce estrogenic effects on bone and uterus in a postmenopausal breast cancer mouse model. Bone 2006; 39:117-124.
20. Datamonitor's productscan online. Available at: http://www.products-can. com/. Accessed July 22, 2008.
21. Singh SR, Levine MA. Natural health product use in Canada: analysis of the National Population Health Survey. Can J Clin Pharmacol 2006; 13:e240-e250.
22. Mazur WM, Wähälä K, Rasku S, Salakka A, Hase T, Adlercreutz H. Lignan and isoflavonoid concentrations in tea and coffee. Br J Nutr 1998;79:37-45.
23. Mazur W. Phytoestrogen content in foods. Baillieres Clin Endocrinol Metab 1998;12:729-742.
24. Nurmi T, Heinonen S, Mazur W, Deyama T, Nishibe S, Adlercreutz H. Lignans in selected wines. Food Chem 2003;83:303-309.
25. Thompson LU, Boucher BA, Cotterchio M, Kreiger N, Liu Z. Dietary phytoestrogens, including isoflavones, lignans, and coumestrol, in non-vitamin, nonmineral supplements commonly consumed by women in Canada. Nutr Cancer 2007;59:176-184.
26. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products, Food and Drug Administration (FDA). April 1994. Available at: http://www.fda.gov/CDER/ GUIDANCE/osteo.pdf. Accessed July 22, 2008.
27. Watkins BA, Reinwald S, Li Y, Seifert MF. Protective actions of soy isoflavones and n-3 PUFAs on bone mass in ovariectomized rats. J Nutr Biochem 2005;16:479-488.
28. Association of Official Analytical Chemists. Official Methods of Analysis. Gaithersburg, MD: AOAC International, 1997.
29. Thompson LU, Boucher BA, Liu Z, Cotterchio M, Kreiger N. Phyto-estrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr Cancer 2006;54:184-201.
30. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226:497-509.
31. Olfert ED, Cross BM, McWilliam AA, eds. Guide to the Care and Use of Experimental Animal., Vol 1., 2nd ed. Ottawa: Canadian Council on Animal Care, 1993.
32. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition Ad Hoc Writing Committee on the reformation of the AIN-76A rodent diet. J Nutr 1993;123:1939-1951.
33. Lee LL, Lee JS, Waldman SD, Casper RF, Grynpas MD. Polycyclic aromatic hydrocarbons present in cigarette smoke cause bone loss in an ovariectomized rat model. Bone 2002;30:917-923.
34. McMillan J, Kinney RC, Ranly DM, Fatehi-Sedeh S, Schwartz Z, Boyan BD. Osteoinductivity of demineralized bone matrix in immuno-compromised mice and rats is decreased by ovariectomy and restored by estrogen replacement. Bone 2007;40:111-121.
35. Vanin CM, MacLusky NJ, Grynpas MD, Casper RF. The effect of three hormone replacement regimens on bone density in the aged oophorec-tomized rat. Fertil Steril 1995;63:643-651.
36. Wyde ME, Seely J, Lucier GW, Walker NJ. Toxicity of chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in diethylnitrosamine-initiated ovariectomized rats implanted with subcutaneous 17β-estradiol pellets. Toxicol Sci 2000;54:493-499.
37. Fonseca D, Ward WE. Daidzein together with calcium preserve bone mass and biomechanical strength at multiple sites in ovariectomized mice. Bone 2004;35:489-497.
38. Reinwald S, Li Y, Moriguchi T, Salem N Jr, Watkins BA. Repletion with (n-3) fatty acids reverses bone structural deficits in (n-3)-deficient rats. J Nutr 2004;134:388-394.
39. Ettinger B. Rationale for use of lower estrogen doses for postmeno-pausal hormone therapy. Maturitas 2007;57:81-84.
40. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyproges-terone acetate on bone in early postmenopausal women. JAMA 2002; 287:2668-2676.
41. Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008;59:2-6.
42. Poulsen RC, Moughan PJ, Kruger MC. Docosahexaenoic acid and 17β-estradiol co-treatment is more effective than 17β-estradiol alone in maintaining bone post-ovariectomy. Exp Biol Med (Maywood) 2008; 233:592-602.
43. Schlemmer CK, Coetzer H, Claassen N, Kruger MC. Oestrogen and essential fatty acid supplementation corrects bone loss due to ovariec-tomy in the female Sprague Dawley rat. Prostaglandins Leukot Essent Fatty Acids 1999;61:381-390.
44. Cai DJ, Zhao Y, Glasier J, et al. Comparative effect of soy protein, soy isoflavones, and 17β-estradiol on bone metabolism in adult ovariectom-ized rats. J Bone Miner Res 2005;20:828-839.
45. Feng J, Shi Z, Ye Z. Effects of metabolites of the lignans enterolactone and enterodiol on osteoblastic differentiation of MG-63 cells. Biol Pharm Bull 2008;31:1067-1070.
46. Bergman Jungeström M, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 2007;13:1061-1067.
47. Chen J, Power KA, Mann J, Cheng A, Thompson LU. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen. Exp Biol Med (Maywood) 2007;232:1071-1080.
48. Dupasquier CM, Dibrov E, Kneesh AL, et al. Dietary flaxseed inhibits atherosclerosis in the LDL receptor-deficient mouse in part through antiproliferative and anti-inflammatory actions. Am J Physiol Heart Circ Physiol 2007;293:H2394-H2402.
49. Childs CE, Romeu-Nadal M, Burdge GC, Calder PC. Gender differences in the n-3 fatty acid content of tissues. Proc Nutr Soc 2008;67:19-27.
50. Sumino H, Ichikawa S, Murakami M, et al. Effects of hormone replacement therapy on circulating docosahexaenoic acid and eico-sapentaenoic acid levels in postmenopausal women. Endocr J 2003;50: 51-59.
51. Giltay EJ, Duschek EJ, Katan MB, Zock PL, Neele SJ, Netelenbos JC. Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women. J Endocrinol 2004;182:399-408.
52. Poulsen RC, Kruger MC. Detrimental effect of eicosapentaenoic acid supplementation on bone following ovariectomy in rats. Prostaglandins Leukot Essent Fatty Acids 2006;75:419-427.
53. Calero JA, Delgado AD, Diaz-Curiel M, et al. Correlation between bone mineral density and bone strength in tibia of rats. Osteoporosis Int 1996; 6:215.
54. Kubota M, Maki K, Sibasaki Y. Correlation between bone density measurement and mechanical properties of bone. Osteoporosis Int 1996;6:215.
55. Archer DF. Neoplasia of the female reproductive tract: effects of hormone therapy. Endocrine 2004;24:259-263.